TFF1 activates p53 through down-regulation of miR-504 in gastric cancer

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5663-5673

  Soutto, Mohammed ^a,b   Chen, Zheng ^b   Saleh, Mohamed A ^b   Katsha, Ahmed ^b   Zhu, Shoumin ^b   Zaika, Alexander ^b   Belkhiri, Abbes ^b   El Rifai, Wael ^a,b,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Gastric cancer; MiR 504; P53; TFF1

Indexed keywords

CISPLATIN; CYCLOHEXIMIDE; INTESTINAL TREFOIL FACTOR; LUCIFERASE; MICRORNA; MICRORNA 504; PROTEIN NOXA; PROTEIN P53; TREFOIL FACTOR 1; UNCLASSIFIED DRUG; MIRN504 MICRORNA, HUMAN; TFF1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL DEATH; COLONY FORMATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; NOXA GENE; NUCLEOTIDE SEQUENCE; PROTEIN ACTIVATION; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TFF1 GENE; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DISEASE MODEL; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, NUDE; MICRORNAS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906225090     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2156     Document Type: Article

References (50)

1. Hayakawa Y, Fox JG, Gonda T, Worthley DL, Muthupalani S and Wang TC. Mouse models of gastric cancer. Cancers. 2013; 5(1):92-130.
2. Weise A and Dunker N. High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6. Histochemistry and cell biology. 2013; 139(2):323-338.
3. Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Correa P, Peek RM, Jr. and El-Rifai W. Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 2011; 121(5):1753-1767.
4. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R and Hanby AM. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(5):2137-2142.
5. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D and Lobie PE. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 2009; 150(10):4473-4483.
6. Corte MD, Tamargo F, Alvarez A, Rodriguez JC, Vazquez J, Sanchez R, Lamelas ML, Gonzalez LO, Allende MT, Garcia-Muniz JL, Fueyo A and Vizoso F. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat. 2006; 96(1):63-72.
7. Buache E, Etique N, Alpy F, Stoll I, Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio MC. Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene. 2011; 30(29):3261-3273.
8. Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A and El-Rifai W. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology. 2013; 145(6):1312-1322 e1311-1318.
9. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P and Rio MC. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996; 274(5285):259-262.
10. Calnan DP, Westley BR, May FE, Floyd DN, Marchbank T and Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol. 1999; 188(3):312-317.
11. Chu G, Qi S, Yang G, Dou K, Du J and Lu Z. Gastrointestinal tract specific gene GDDR inhibits the progression of gastric cancer in a TFF1 dependent manner. Molecular and cellular biochemistry. 2012; 359(1-2):369-374.
12. Ge Y, Zhang J, Cao J, Wu Q, Sun L, Guo L and Wang Z. TFF1 inhibits proliferation and induces apoptosis of gastric cancer cells in vitro. Bosnian journal of basic medical sciences/Udruzenje basicnih mediciniskih znanosti = Association of Basic Medical Sciences. 2012; 12(2):74-81.
13. Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol. 2002; 157(5):761-770.
14. Levine AJ, Feng Z, Mak TW, You H and Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes & development. 2006; 20(3):267-275.
15. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307-310.
16. Vousden KH and Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-431.
17. Kerr JF, Wyllie AH and Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British journal of cancer. 1972; 26(4):239-257.
18. Levine AJ, Hu W and Feng Z. The P53 pathway: what questions remain to be explored? Cell death and differentiation. 2006; 13(6):1027-1036.
19. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M and Putzer BM. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. The Journal of biological chemistry. 2003; 278(16):14230-14236.
20. Harris SL and Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24(17):2899-2908.
21. Brooks CL and Gu W. p53 ubiquitination: Mdm2 and beyond. Molecular cell. 2006; 21(3):307-315.
22. Haupt S, Berger M, Goldberg Z and Haupt Y. Apoptosis-the p53 network. Journal of cell science. 2003; 116(Pt 20):4077-4085.
23. Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S, Nosrati M, Sagebiel R, Miller JR, 3rd and Kashani-Sabet M. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. Journal of the National Cancer Institute. 2013; 105(6):433-442.
24. Feng Z, Zhang C, Wu R and Hu W. Tumor suppressor p53 meets microRNAs. Journal of molecular cell biology. 2011; 3(1):44-50.
25. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR and Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current biology: CB. 2007; 17(15):1298-1307.
26. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular cell. 2007; 26(5):731-743.
27. He L, He X, Lowe SW and Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nature reviews Cancer. 2007; 7(11):819-822.
28. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ and Feng Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Molecular cell. 2010; 38(5):689-699.
29. Tanaka T, Nakamura J, Kitajima Y, Kai K, Miyake S, Hiraki M, Ide T, Koga Y and Noshiro H. Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. International journal of oncology. 2013; 42(3):894-902.
30. Feng G, Zhang Y, Yuan H, Bai R, Zheng J, Zhang J and Song M. DNA methylation of trefoil factor 1 (TFF1) is associated with the tumorigenesis of gastric carcinoma. Molecular medicine reports. 2014; 9(1):109-117.
31. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T and Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994; 78(4):703-711.
32. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R and Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome biology. 2013; 14(4):R32.
33. Lavin MF and Gueven N. The complexity of p53 stabilization and activation. Cell death and differentiation. 2006; 13(6):941-950.
34. Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MY, Jeng YM, Kuo ML and Chang CC. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene. 2012; 31(19):2401-2411.
35. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF and Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes & development. 2009; 23(7):862-876.
36. Ribieras S, Tomasetto C and Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta. 1998; 1378(1):F61-77.
37. Shi SQ, Cai JT and Yang JM. Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer. World journal of gastroenterology: WJG. 2006; 12(19):3119-3122.
38. Yokota I, Sasaki Y, Kashima L, Idogawa M and Tokino T. Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. International journal of oncology. 2010; 37(6):1407-1416.
39. Amundson SA, Myers TG and Fornace AJ, Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 1998; 17(25):3287-3299.
40. Li B and Lee MY. Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. The Journal of biological chemistry. 2001; 276(32):29729-29739.
41. Reisman D and Boggs K. Transcriptional regulation of the p53 tumor suppressor gene: a potential target for cancer therapeutics? Recent patents on DNA & gene sequences. 2007; 1(3):176-185.
42. Reisman D, Takahashi P, Polson A and Boggs K. Transcriptional Regulation of the p53 Tumor Suppressor Gene in S-Phase of the Cell-Cycle and the Cellular Response to DNA Damage. Biochemistry research international. 2012; 2012:808934.
43. Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B and Lodish HF. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Molecular and cellular biology. 2009; 29(19):5290-5305.
44. Prest SJ, May FE and Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002; 16(6):592-594.
45. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM. The role of p53 in apoptosis. Discovery medicine. 2010; 9(45):145-152.
46. Shi C, Shin YO, Hanson J, Cass B, Loewen MC and Durocher Y. Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells. Biochemistry. 2005; 44(48):15705-15714.
47. Smale ST. Beta-galactosidase assay. Cold Spring Harbor protocols. 2010; 2010(5):pdb prot5423.
48. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010; 115(25):5202-5213.
49. Saad R, Chen Z, Zhu S, Jia P, Zhao Z, Washington MK, Belkhiri A and El-Rifai W. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PloS one. 2013; 8(5):e64463.
50. El-Rifai W, Moskaluk CA, Abdrabbo M, Harper JC, Yoshida C, Riggins G, Frierson HF, Jr. and Powell SM. Gastric Cancers Overexpress S100A calcium binding proteins. Cancer Res. 2002; 62:6823-6826.